- Conditions
- Invasive Meningococcal Disease
- Interventions
- Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV., Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV., Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine., Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 484 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Madera, California • Paramount, California + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 36
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Meningococcal Vaccine
- Interventions
- MenABCWY, Saline, rLP2086, MenACWY-CRM
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 1,610 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Fountain Hills, Arizona + 45 more
- Conditions
- Prevention of Meningococcal Disease
- Interventions
- MenACWY-CRM conjugate vaccine, adjuvanted, MenACWY-CRM conjugate vaccine, unadjuvanted, MenACWY polysaccharide vaccine
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 524 participants
- Timeline
- 2004 – 2006
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • Pittsburgh, Pennsylvania • Seattle, Washington
- Conditions
- Meningococcal Meningitis
- Interventions
- Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
- Biological
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 11 Years to 18 Years
- Enrollment
- 801 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Fremont, California • Madera, California + 14 more
- Conditions
- Meningococcal Infections, Meningococcal Meningitis
- Interventions
- MenACWY CRM, Meningococcal ACWY Conjugate vaccine
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 11 Years to 55 Years
- Enrollment
- 3,539 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Fremont, California + 37 more
- Conditions
- Meningococcal Meningitis
- Interventions
- MenACWY-CRM conjugate vaccine, Licensed comparator
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 11 Years to 18 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Fremont, California • Fresno, California + 21 more
- Conditions
- Meningococcal Disease
- Interventions
- MenABCWY+OMV, MenABCWY+¼OMV, Placebo
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 194 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Madera, California • Paramount, California + 5 more
- Conditions
- Meningococcal Vaccine
- Interventions
- MenABCWY, Saline, Trumenba, MenACWY-CRM
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 2,431 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Banning, California + 49 more
- Conditions
- Infections, Meningococcal
- Interventions
- Meningococcal vaccine GSK134612
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 9 Months to 9 Months
- Enrollment
- 385 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Benton, Arkansas • Little Rock, Arkansas + 15 more
- Conditions
- Meningococcal Disease
- Interventions
- MenABCWY, Placebo, MenACWY
- Biological · Other
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 305 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 8
- States / cities
- Huntsville, Alabama • Jonesboro, Arkansas • Melbourne, Florida + 5 more
- Conditions
- Infections, Meningococcal
- Interventions
- Nimenrix, Blood sampling
- Biological · Procedure
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 15 Years to 30 Years
- Enrollment
- 818 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2013
- U.S. locations
- 10
- States / cities
- Daly City, California • Fairfield, California • Redwood City, California + 6 more
- Conditions
- Meningococcal Disease, Meningococcal Meningitis
- Interventions
- Novartis Meningococcal (MenACWY-CRM) vaccine
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 16 Years to 23 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • Pittsburgh, Pennsylvania • Seattle, Washington
- Conditions
- HPV
- Interventions
- Brief Provider Training - Bundled Approach, Brief Provider Training - Benefits Approach, Parent Interactive Text Message - Bundled Approach, Parent Interactive Text Message - Benefits Approach
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 8,043 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Infections, Meningococcal
- Interventions
- rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), Placebo, MenABCWY-1, MenABCWY-2, MenABCWY-3
- Combination Product · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 3,657 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 64
- States / cities
- Chandler, Arizona • Glendale, Arizona • Jonesboro, Arkansas + 51 more
- Conditions
- Neisseria Meningitidis
- Interventions
- Trumenba, PENBRAYA
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Shigellosis
- Interventions
- Shigella 4V, MenACWY, Rabies, Diphtheria, Tetanus and Pertussis (DTaP), Placebo
- Biological
- Lead sponsor
- LimmaTech Biologics AG
- Industry
- Eligibility
- 8 Months to 50 Years
- Enrollment
- 597 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 0
- States / cities
- Not listed
- Conditions
- Meningococcal Disease
- Interventions
- MenACWY-CRM, DTaP-IPV/Hib, HBV, PCV, MMR
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 55 Days to 89 Days
- Enrollment
- 529 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more
- Conditions
- Meningococcal Disease, Infections, Meningococcal
- Interventions
- Meningococcal quadrivalent CRM-197 conjugate vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 2 Months to 23 Months
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Meningococcal Meningitis
- Interventions
- Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 37 Months to 63 Months
- Enrollment
- 433 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Downey, California • Oakland, California + 15 more
- Conditions
- Meningitis, Meningococcal
- Interventions
- MenABCWY vaccine, Placebo, MenACWY vaccine, MenB vaccine
- Combination Product · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 15 Years to 25 Years
- Enrollment
- 1,250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 48
- States / cities
- Jonesboro, Arkansas • Banning, California • Chula Vista, California + 42 more
- Conditions
- Prevention of Meningococcal Disease
- Interventions
- MenACWY-CRM Vaccine, MenACWY-PS Vaccine
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 12 Months to 10 Years
- Enrollment
- 910 participants
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Meningococcal Infections
- Interventions
- MenACWY-CRM + MMRV, MMRV, MenACWY-CRM
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 7 Months to 1 Year
- Enrollment
- 1,630 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Greenville, Alabama + 69 more
- Conditions
- Infections, Meningococcal
- Interventions
- Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid), Placebo
- Combination Product · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 16 Years to 18 Years
- Enrollment
- 945 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Bell Gardens, California • Los Angeles, California + 35 more
- Conditions
- Infections, Meningococcal
- Interventions
- MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, MenB vaccine, MenACWY vaccine
- Combination Product · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 10 Years to 50 Years
- Enrollment
- 1,440 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 12
- States / cities
- Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more